Our CFO, Jacob Michlewicz and CDO, Mark Farmery, will be present. Reach out if you would like to connect during the conference.
Please find Anocca’s annual report for 2021 on the link below.
Read moreOur CTO, Luke Pase, will join the conference and take part in a panel discussing the next chapter for gene editing in allogeneic cell therapy development. Reach out if you would like to connect…
Read moreSödertälje, Sweden, 7th April 2022 – Anocca, a biotechnology company using its precision biology platforms to engineer a broad portfolio of innovative T cell therapeutics, today announced the…
Read moreOur CSO, Hugh Salter, will present our systematic platform approach to the identification of actionable CD8 antigens & TCRs. Contact us if you would like to connect during the conference.
Read moreOur CDO, Mark Farmery, will deliver an in-person company presentation, describing our industrialised approach to TCR-T cell therapy development. Contact us if you would like to connect during the conference.
Read moreSödertälje, Sweden, February 22, 2022 – Anocca AB, a pioneer in T cell immunotherapy, today announces it has made a number of appointments to expand its senior leadership team and strengthen its business development and R&D capabilities. This includes the…
Read moreOriginally published in BioCentury. Anocca is using engineered human cells to recapitulate the T cell immune system ex vivo, eliminating the person-to-person variability in working with primary T cells from patients, to create standardized, scalable TCR-modified T…
Read moreOur CEO, Reagan Jarvis, is speaking in the panel “Advances in Cell & Gene Therapies”. Reach out to us if you would like to connect.
Read moreSödertälje, Sweden, 9 November 2021 – Anocca AB, a leader in unlocking the potential of T cell immunotherapy to deliver transformative T cell receptor engineered T cell therapeutics (TCR-T), today announced it has appointed a new Head of Clinical Development, Sandra…
Read moreOriginally published in BioWorld. DUBLIN – Anocca AB raised $47 million in a series B round to advance its T-cell-based immunotherapies expressing recombinant T-cell receptors (TCRs) toward clinical trials in cancer and to build out its manufacturing capacity at its…
Read moreOriginally published in Labiotech.eu. Swedish firm Anocca’s fundraising is the first major venture capital round to go to a European TCR therapy developer this year; another sign that the technology is gaining momentum. Last year was a busy one for companies…
Read moreOriginally published in Endpoints News. Södertälje, Sweden, the historic home to the Astra half of AstraZeneca, may seem an unlikely place for cutting-edge R&D on T cell receptors and cell therapies. And Reagan Jarvis — a transplant from New Zealand who had spent…
Read moreSödertälje, 22 juli 2021 – Anocca AB, ett världsledande svenskt bioteknikbolag för utveckling av T-cellsbehandlingar mot cancer, autoimmuna sjukdomar och virusinfektioner, meddelade idag att bolaget har stängt en serie B-finanseringsrunda på 400 miljoner kronor …
Read moreSödertälje, Sweden, 22 July 2021 – Anocca AB, a leader in unlocking the potential of T-cell immunotherapy to deliver transformative therapeutics for cancer, today announced the closing of a USD 47 million (SEK 400 million) Series B financing to further advance the…
Read moreOriginally published in Scrip. SWEDEN-BASED ANOCCA AB WILL USE A just completed $47m Series B financing to advance its industrialised cellular biology platform and pipeline of TCR-T cellular therapies into Phase I/IIa oncology clinical trials, its CEO tells Scrip….
Read moreOriginally published in BioWorld. DUBLIN – Anocca AB raised $47 million in a series B round to advance its T-cell-based immunotherapies expressing recombinant T-cell receptors (TCRs) toward clinical trials in cancer and to build out its manufacturing capacity at its…
Read moreOriginally published in Labiotech.eu. Swedish firm Anocca’s fundraising is the first major venture capital round to go to a European TCR therapy developer this year; another sign that the technology is gaining momentum. Last year was a busy one for companies…
Read more
